) survival times were 12.5 (2-195) days for trisomy 13 and 9 (2-92) days for trisomy 18. Mean 1-year survival for trisomy 13 was 19.8% (95% CI, 14.2%-26.1%) and 12.6% (95% CI, 8.9%-17.1%) for trisomy 18. Ten-year survival for trisomy 13 was 12.9% (95% CI, 8.4%-18.5%) and 9.8% (95% CI, 6.4%-14.0%) for trisomy 18. Survival did not change over the study period. Forty-one children (23.6%) with trisomy 13 and 35 children (13.8%) with trisomy 18 underwent surgeries, ranging from myringotomy to complex cardiac repair. Median age at first surgery for trisomy 13 was 92 (IQR, 30.5-384.5) days and for trisomy 18, it was 205.5 (IQR, 20.0-518.0) days. Kaplan-Meier curves showed 1-year survival after first surgery of 70.7% (95% CI, 54.3%-82.2%; n = 23) for trisomy 13 and 68.6% (95% CI, 50.5%-81.2%; n = 29) for trisomy 18.
vivors with trisomy 18 are described as socially interactive with significant motor and cognitive delays (eg, verbalizing a few words); children with trisomy 13 also have severe neurologic impairment. 8 Knowledge about the quality of life of children with trisomy 13 and 18 is limited. 9 Several studies have highlighted the need for better description of longer-term survivors. 3, 10 Lack of information about longer-term survival complicates clinical decision making. Common anomalies that may require intervention include cardiac septal defects in both trisomy 13 and 18 and cleft palate in trisomy 13.
1 Common surgeries in this population include feeding-related (eg, Nissen fundoplication), cardiac, and orthopedic interventions. 11 However, surgical interventions for children with trisomy 13 and 18 are controversial. 8, 10, 12 Some clinicians argue that interventions, especially cardiac procedures, are futile, 12, 13 in part because of extrapolation of early mortality statistics. More data about survival in general and after interventions are important to guide decision making. This study describes survival and surgical procedures over a 22-year period among children with trisomy 13 and 18 in Ontario, Canada's largest province, with a population of approximately 13 million.
Methods

Study Data
Children were followed-up over time in multiple health administrative and demographic data sources in the singlepayer health care system in Ontario. These data sets were linked by encoded identifiers and analyzed at the Institute for Clinical Evaluative Sciences (ICES .0-Q91.3) on a hospital record in the first year of life were included. To ensure accurate calculation of incidence, children were excluded if they were not Ontario residents at birth or, among children missing birth records, if they were not hospitalized in the first 7 days of life. Children with irreconcilable data errors, including no valid identifier for linkage, uncertain genetic diagnosis (equal diagnosis codes for trisomy 13 and 18 or a diagnosis code for trisomy 21) , and birth dates occurring after death dates were also excluded. Data are reported by fiscal year (April 1 to March 31).
Survival
Survival was calculated using death dates from the Ontario Vital Statistics Death File (available through 2012) and the Registered Persons Database. At study end (March 31, 2013), children without death data were censored from the date of their most recent clinical encounter. To meet privacy requirements, survival curves were truncated when 6 children remained.
Surgeries
Hospital records were evaluated for procedure codes through March 31, 2013. Procedures were classified into organ system categories according to coding system chapter (eg, codes starting with 47 in the Canadian Classification of Procedures were labeled cardiac). Surgeries, defined as procedures likely performed in an operating room, were identified using a scheme published by the US Healthcare Cost and Utilization Project.
of stay was also used to create a hierarchy of surgeries within each organ system (eAppendix in the Supplement).
To avoid double-counting complex surgeries with multiple procedure codes, children with multiple procedures in the same organ system on the same date were assessed. Using the hierarchy in eAppendix (in the Supplement), the primary surgery by organ system and date was included in the analysis. Three pediatrician authors (K.E.N., S.M., A.G.) reviewed surgery categorization and application of the hierarchy to multiple procedure codes. Details are available from the authors.
Covariates
Birth weight and postal code were obtained from the birth record. Census-based markers of rurality and socioeconomic status were derived from postal codes. The Rurality Index of Ontario, which assesses population density and health care access, defined rural or urban residence. 16 
Analyses
Comparisons of demographic characteristics of children with trisomy 13 and 18 with those of the general Ontario newborn population were made using χ 2 tests. Clinical characteristics of children surviving 7 days to 1 year were compared with those surviving more than 1 year using Wilcoxon rank-sum tests for birth weight and χ 2 tests for sex, cytogenetic status, income quintile, rurality, and type and number of organ systems affected by congenital anomalies. Kaplan-Meier survival curves were created for children with trisomy 13 and 18 and for survival after first surgery for those undergoing surgeries. To test if survival statistics were inflated by inappropriate inclusion of children in the cohorts, a sensitivity analysis evaluated a more stringent case definition, which required that children with more than 1 hospitalization have more than 1 discharge diagnosis code of trisomy 13 or 18. Survival among the full cohort was compared with survival of those meeting the stricter definition with a log-rank test. Conditional survival, which is the likelihood of surviving to the next time point among children alive at the previous time point, was calculated. Birth prevalence was graphed over time using loess curves, which are unrestricted nonparametric curves. Trends in birth prevalence were modeled using negative binomial regression, and rates were generated using Ontario live births as an offset. The association of birth year with survival time was tested with a Cox proportional hazards model, using year as an independent predictor. The Cox models did not contain timedependent covariates. The proportional hazards assumption was tested graphically and statistically and was satisfied in all models. To investigate potential bias from comparing older and newer cohorts, a sensitivity analysis using the Cox models tested short-term survival (maximum 2 years) to ensure more homogeneous populations. Negative binomial regression models were used to assess change in frequency of surgeries over time and were adjusted for age categories to account for changing age distributions. These models included data from all surgeries, including surgeries performed on the same child at different times. Median age at procedure and postoperative survival were calculated for the most common surgeries. To maximize information while meeting privacy requirements, median age and postoperative survival were assessed based on the following criteria: (1) procedures (ie, 1 child undergoing 2 surgeries would contribute separate data for each procedure); and (2) individual children. R version 3.1.2 was used to compare cohort demographics with the general Ontario newborn population and to evaluate birth prevalence over time; all other analyses were performed using SAS version 6.1. Testing was 2-sided, and P values less than .05 were considered significant.
Results
Demographics and Prevalence
In Table 1) . eTable 1 in the Supplement shows the most common congenital anomaly diagnoses by organ system. The incidence of trisomy 13 and 18 was stable over time with mean birth rates for trisomy 13 of 6.0 (95% CI, 5.2-7.0) and for trisomy 18 of 8.8 (95% CI, 7.7-9.9) per 100 000 live births (eFigure 2 in the Supplement).
Survival
Children with trisomy 13 and 18 were observed from 0 to more than 7000 days. At the end of follow-up, 24 children with trisomy 13 and 23 children with trisomy 18 were alive; 7 children with either trisomy (1.6%) left the province before the end of the study. The primary analysis had no missing data. Survival did not change over time. Hazard ratios for birth year were 1.00 (95% CI, 0.97-1.03) for trisomy 13 and 1.00 (95% CI, 0.98-1.03) for trisomy 18. This finding was unchanged when maximum survival was limited to 2 years. Median survival time for children with trisomy 13 was 12.5 (IQR, 2-195) days and for trisomy 18 it was 9 (IQR, 2-92) days ( Figure 1) . Children meeting the stricter case definition had a shorter median survival time of 7.5 (IQR, 1-94) days for trisomy 13 and 6 (IQR, 1-74) days for trisomy 18, but their overall survival was not statistically different by log-rank test (P = .14 for trisomy 13; P = .24 for trisomy 18). Early deaths were common, but fewer deaths occurred after 3 months in 
Discussion
Among children with trisomy 13 and 18 born in Ontario between 1991 and 2012, longer-term survival and use of surgi- 
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Survival and Surgical Interventions for Children With Trisomy 13 and 18 children surviving 6 months lived 10 years or longer. Many prior studies did not evaluate survival beyond 1 year. [22] [23] [24] [25] Four studies (2 studies for trisomy 18 only 3,26 and 2 studies for both 7, 27 ) identified individuals living beyond 5 years. The most recent study reported 5-year survival of 9.7% for children with trisomy 13 and 12.9% among children with trisomy 18. 7 In this study, cardiac and neurological diagnoses were not associated with shorter survival, and children with shorter survival did not have anomalies in more organ systems. One prior study also found no association between cardiac defects and survival. 3 More than 20% of children with trisomy 13 and more than 10% of children with trisomy 18 in this study underwent 1 or more interventions, ranging from minor procedures (eg, myringotomy) to major cardiac repairs (eg, hemi-Fontan). Oneyear survival after first surgery was approximately 70%. Given the debate about surgery in these populations, 13, 28, 29 this survival likely reflects both careful patient selection and procedural benefit. One prior population-based study reported 2 surgeries among 30 children with trisomy 13 and none for 67 children with trisomy 18. 22 Previous case series about surgeries have reported 1-year survival of 17% to 100%. 30, 31 No studies have explored how quality-of-life factors into decision making around procedural benefit. 32 One factor likely contributing to higher survival and intervention rates found in this study was the use of health administrative data. Ontario's single-payer health care system captures all surgical procedures and deaths, and children leaving the province were censored after their last clinical encounter. In contrast, most population-based studies use birth defect registries, which rely on case notification by hospital or laboratory personnel. Most registry-based studies use posthoc linkage to death registries to calculate survival, which creates challenges when children do not have verified dates of death at end of follow-up. Although some researchers used ancillary data to confirm vital status, other studies either excluded children without death dates or assumed children were alive at study end. eTable 6 (in the Supplement) describes study approaches to missing data. Differing strategies can substantially affect survival statistics. Two recent studies used data from the same registry over similar time periods (1985-2003 and 1985-2007) . One study 22 reported 1-year survival of 13.8% for trisomy 13 and of 1.6% for trisomy 18; the other study 33 reported 1-year survival of 3.3% for trisomy 13 and of 6.0% for trisomy 18. Additionally, many registry-based studies did not have access to medical records, including surgeries. a Per institutional policy, data were suppressed for cell sizes of less than 6 children to ensure nonidentification. b Specific surgery types are detailed in eTable 4a (in the Supplement).
c Outcomes including all procedures may include the same child more than once.
d Calculated from discharge date when the intervention date was not available.
Administrative data sources have limitations, especially related to cohort creation. Unlike registry-based studies with laboratory-confirmed diagnoses, this study defined the population with diagnostic codes listed on hospital discharge records. Study population underascertainment could arise from several causes. Infants could die before diagnosis, but this would be uncommon because most trisomy 13 and 18 diagnoses are established prenatally. 22 When liveborn infants die soon after birth, including in the delivery room, both a hospital discharge record and a death certificate are required. Diagnostic data and cause of death are ascertained by the same physician so the hospital record should include the presumptive diagnosis. This study's reliance on hospital records would miss home births resulting in out-of-hospital deaths; however, that scenario would be rare for 2 reasons. In Ontario, home deliveries by midwives are not currently used for palliative care or for infants with abnormal prenatal diagnoses. Also, clinical policy specifies that infants born at home with previously undiagnosed congenital anomalies are to be transferred to a hospital. The use of administrative data also means that the study cohort might include children without a laboratory-confirmed diagnosis of trisomy 13 or 18, or children whose records were mistakenly coded. However, sensitivity analyses showed no difference in survival with a stricter case definition. Additionally, the prevalence reported for trisomy 13 and 18 (6.0 and 8.8 per 100 000 live births) was on the lower end of previously described ranges of 4-13.6 for trisomy 13 22, 36 and 8.5-90 for trisomy 18. 22,37 If the cohort contained a large proportion of misclassified children, the birth prevalence would likely be inflated. Also, frequencies of diagnoses for specific congenital anomalies were similar to those in other studies. 38 A general validity analysis of diagnostic codes in this study's data source demonstrated a positive predictive value of 0.82 (IQR, 0.74-0.89). 39 The most important study limitation is the lack of quality-of-life measures to add important context to the survival data; this study alone is insufficient to support decision mation about neurocognitive developmental outcomes is sparse, with a few small studies describing a spectrum of disability.
5,9 In addition to this study's data about survival duration, measurement of quality of life in the context of major surgeries will be important to help families and clinicians balance the risks and benefits of interventions. This study has several other limitations. First, identification of children with mosaic or translocation-type trisomy 13 and 18 was incomplete. The ICD-9 codes used before 2002 did not specify cytogenetic diagnosis. As in other studies in which cytogenetic status could not be verified, 3, 7, 23, 33, 35 children with mosaic-and translocation-type trisomy were included in this study's primary analysis. This decision likely increased rates of longer-term survival compared with studies including only children with full trisomy 13 or 18. Second, 7 children (1.6%) left the province before the end of follow-up and they may have had subsequent uncaptured surgical procedures. Third, data on prenatal diagnoses, terminations, and miscarriages were unavailable, so this study reports liveborn prevalence rather than true prevalence. Fourth, to meet privacy requirements, procedures were grouped by organ system and may include data on multiple surgeries from the same child, even though these groupings are not homogeneous, and individual rates would be more clinically relevant. Also the number and heterogeneity of the procedures limits the analysis of surgical timing and postoperative survival trends. Further, this study cannot determine if interventions caused longer survival. However, because of the rarity of these diagnoses and variability in their presentation, it is challenging to generate definitive evidence about intervention efficacy. In particular, the randomized clinical trial necessary to test for a causal relationship between surgery and survival would be neither ethical nor feasible so the information available from administrative data, while incomplete, is useful. This study did not assess for comorbidities other than congenital anomalies because of the risk of time confounding the association between comorbidities and survival. For example, the increased number of neurologic congenital anomaly diagnoses among longer-term survivors with trisomy 18 likely reflects an increased probability of undergoing neuroimaging over time. Additionally, the study data do not include details on important demographic and clinical factors or family treatment goals.
Conclusions
Among children born with trisomy 13 or 18 in Ontario, early mortality was the most common outcome, but 10% to 13% survived for 10 years. Among children who underwent surgical interventions, 1-year survival was high.
